Review of TA75 Interferon alfa and ribavirin for treating chronic hepatitis C, TA106 Peginterferon alfa and ribavirin for treating mild hepatitis C, and TA200 Pegylated interferons, peginterferon alfa, ribavirin and alfa interferon for treating hepatitis C

Proposal to move the existing guidance to the static list

The planned date for review of TA200 was July 2013. TA75 and TA106 are static guidance and have no set review date.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

At this time, there is no new evidence that would lead to a change in the existing recommendations for TA75, TA106 or TA200. However, the recommendations for the use of peginterferons and ribavirin are now very fragmented, and it would be beneficial to bring all of the existing recommendations together in the context of wider clinical practice.  The best place for this to take place would be within a clinical guideline.

The Institute is currently consulting on plans for the commencement of the clinical guideline on the management of hepatitis C to be deferred until the assessment of new technologies (such as sofosbuvir) has been completed by the technology appraisals programme.

As there is no evidence to warrant an update within the technology appraisals programme, we propose that TA200 should be moved to the static list of technology appraisals, and that TA75 and TA106 should remain on the static list until the development of the clinical guideline commences.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. Please see appendix A for a full list of the organisations we have contacted. 

October 2013